vs

Side-by-side financial comparison of ALLEGRO MICROSYSTEMS, INC. (ALGM) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.

ALLEGRO MICROSYSTEMS, INC. is the larger business by last-quarter revenue ($229.2M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 28.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -2.4%).

Allegro MicroSystems, Inc. is a global semiconductor firm designing and manufacturing high-performance power and sensing integrated circuits. Its core products include magnetic sensors, power ICs, and motion control solutions, serving automotive, industrial, consumer electronics, and communications markets worldwide.

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

ALGM vs ESPR — Head-to-Head

Bigger by revenue
ALGM
ALGM
1.4× larger
ALGM
$229.2M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+114.9% gap
ESPR
143.7%
28.9%
ALGM
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
-2.4%
ALGM

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ALGM
ALGM
ESPR
ESPR
Revenue
$229.2M
$168.4M
Net Profit
$8.3M
Gross Margin
46.7%
Operating Margin
4.2%
50.6%
Net Margin
3.6%
Revenue YoY
28.9%
143.7%
Net Profit YoY
221.0%
EPS (diluted)
$0.04
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALGM
ALGM
ESPR
ESPR
Q4 25
$229.2M
$168.4M
Q3 25
$214.3M
$87.3M
Q2 25
$203.4M
$82.4M
Q1 25
$192.8M
$65.0M
Q4 24
$177.9M
$69.1M
Q3 24
$187.4M
$51.6M
Q2 24
$166.9M
$73.8M
Q1 24
$240.6M
$137.7M
Net Profit
ALGM
ALGM
ESPR
ESPR
Q4 25
$8.3M
Q3 25
$6.5M
$-31.3M
Q2 25
$-13.2M
$-12.7M
Q1 25
$-14.8M
$-40.5M
Q4 24
$-6.9M
Q3 24
$-33.7M
$-29.5M
Q2 24
$-17.7M
$-61.9M
Q1 24
$-7.1M
$61.0M
Gross Margin
ALGM
ALGM
ESPR
ESPR
Q4 25
46.7%
Q3 25
46.3%
Q2 25
44.9%
Q1 25
41.4%
Q4 24
45.7%
Q3 24
45.7%
Q2 24
44.8%
Q1 24
51.2%
Operating Margin
ALGM
ALGM
ESPR
ESPR
Q4 25
4.2%
50.6%
Q3 25
2.9%
-11.4%
Q2 25
-1.3%
8.6%
Q1 25
-6.8%
-34.0%
Q4 24
-0.0%
-6.4%
Q3 24
2.2%
-31.0%
Q2 24
-6.4%
3.5%
Q1 24
6.6%
52.5%
Net Margin
ALGM
ALGM
ESPR
ESPR
Q4 25
3.6%
Q3 25
3.0%
-35.9%
Q2 25
-6.5%
-15.4%
Q1 25
-7.7%
-62.2%
Q4 24
-3.9%
Q3 24
-18.0%
-57.2%
Q2 24
-10.6%
-83.9%
Q1 24
-3.0%
44.3%
EPS (diluted)
ALGM
ALGM
ESPR
ESPR
Q4 25
$0.04
$0.32
Q3 25
$0.03
$-0.16
Q2 25
$-0.07
$-0.06
Q1 25
$-0.08
$-0.21
Q4 24
$-0.04
$-0.14
Q3 24
$-0.18
$-0.15
Q2 24
$-0.09
$-0.33
Q1 24
$-0.04
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALGM
ALGM
ESPR
ESPR
Cash + ST InvestmentsLiquidity on hand
$155.2M
$167.9M
Total DebtLower is stronger
$280.7M
Stockholders' EquityBook value
$962.7M
$-302.0M
Total Assets
$1.4B
$465.9M
Debt / EquityLower = less leverage
0.29×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALGM
ALGM
ESPR
ESPR
Q4 25
$155.2M
$167.9M
Q3 25
$117.5M
$92.4M
Q2 25
$129.1M
$86.1M
Q1 25
$121.3M
$114.6M
Q4 24
$138.5M
$144.8M
Q3 24
$188.8M
$144.7M
Q2 24
$173.1M
$189.3M
Q1 24
$212.1M
$226.6M
Total Debt
ALGM
ALGM
ESPR
ESPR
Q4 25
$280.7M
Q3 25
$280.4M
Q2 25
$304.8M
Q1 25
$338.9M
Q4 24
$368.7M
Q3 24
$393.0M
Q2 24
$195.8M
Q1 24
$245.1M
Stockholders' Equity
ALGM
ALGM
ESPR
ESPR
Q4 25
$962.7M
$-302.0M
Q3 25
$944.2M
$-451.4M
Q2 25
$922.7M
$-433.5M
Q1 25
$929.6M
$-426.2M
Q4 24
$933.0M
$-388.7M
Q3 24
$937.3M
$-370.2M
Q2 24
$1.1B
$-344.2M
Q1 24
$1.1B
$-294.3M
Total Assets
ALGM
ALGM
ESPR
ESPR
Q4 25
$1.4B
$465.9M
Q3 25
$1.4B
$364.0M
Q2 25
$1.4B
$347.1M
Q1 25
$1.4B
$324.0M
Q4 24
$1.4B
$343.8M
Q3 24
$1.5B
$314.1M
Q2 24
$1.4B
$352.3M
Q1 24
$1.5B
$373.1M
Debt / Equity
ALGM
ALGM
ESPR
ESPR
Q4 25
0.29×
Q3 25
0.30×
Q2 25
0.33×
Q1 25
0.36×
Q4 24
0.40×
Q3 24
0.42×
Q2 24
0.18×
Q1 24
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALGM
ALGM
ESPR
ESPR
Operating Cash FlowLast quarter
$45.4M
$45.2M
Free Cash FlowOCF − Capex
$41.3M
FCF MarginFCF / Revenue
18.0%
Capex IntensityCapex / Revenue
1.8%
0.0%
Cash ConversionOCF / Net Profit
5.47×
TTM Free Cash FlowTrailing 4 quarters
$121.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALGM
ALGM
ESPR
ESPR
Q4 25
$45.4M
$45.2M
Q3 25
$20.4M
$-4.3M
Q2 25
$61.6M
$-31.4M
Q1 25
$20.4M
$-22.6M
Q4 24
$-8.2M
$-35.0M
Q3 24
$15.5M
$-35.3M
Q2 24
$34.2M
$-7.2M
Q1 24
$12.8M
$53.8M
Free Cash Flow
ALGM
ALGM
ESPR
ESPR
Q4 25
$41.3M
Q3 25
$13.9M
Q2 25
$51.0M
Q1 25
$15.0M
Q4 24
$-21.8M
Q3 24
$5.6M
$-35.5M
Q2 24
$23.2M
$-7.3M
Q1 24
$-1.5M
$53.8M
FCF Margin
ALGM
ALGM
ESPR
ESPR
Q4 25
18.0%
Q3 25
6.5%
Q2 25
25.1%
Q1 25
7.8%
Q4 24
-12.3%
Q3 24
3.0%
-68.7%
Q2 24
13.9%
-9.9%
Q1 24
-0.6%
39.0%
Capex Intensity
ALGM
ALGM
ESPR
ESPR
Q4 25
1.8%
0.0%
Q3 25
3.0%
0.0%
Q2 25
5.2%
0.0%
Q1 25
2.8%
0.0%
Q4 24
7.7%
0.0%
Q3 24
5.3%
0.3%
Q2 24
6.6%
0.1%
Q1 24
5.9%
0.1%
Cash Conversion
ALGM
ALGM
ESPR
ESPR
Q4 25
5.47×
Q3 25
3.12×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALGM
ALGM

Automotive End Market$164.5M72%
Industrial And Other End Market$64.7M28%

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

Related Comparisons